BR112023003492A2 - Composto de fórmula (i), composição farmacêutica e uso do composto - Google Patents

Composto de fórmula (i), composição farmacêutica e uso do composto

Info

Publication number
BR112023003492A2
BR112023003492A2 BR112023003492A BR112023003492A BR112023003492A2 BR 112023003492 A2 BR112023003492 A2 BR 112023003492A2 BR 112023003492 A BR112023003492 A BR 112023003492A BR 112023003492 A BR112023003492 A BR 112023003492A BR 112023003492 A2 BR112023003492 A2 BR 112023003492A2
Authority
BR
Brazil
Prior art keywords
compound
formula
pharmaceutical composition
cocrystal
bronchiectasis
Prior art date
Application number
BR112023003492A
Other languages
English (en)
Inventor
Li Yao
Shi Zongjun
Zhang Guobiao
Chen Lei
Wang Wenjing
Zhang Xiaobo
Zheng Dengyu
Xu Bo
Liu Xin
Wang Yajun
Ye Fei
TANG Pingming
Ni Jia
Zhang Chen
Yan Pangke
Original Assignee
Haisco Pharmaceuticals Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haisco Pharmaceuticals Pte Ltd filed Critical Haisco Pharmaceuticals Pte Ltd
Publication of BR112023003492A2 publication Critical patent/BR112023003492A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSTO DE FÓRMULA (I), COMPOSIÇÃO FARMACÊUTICA E USO DO COMPOSTO. É divulgado um composto derivado de nitrila representado pela fórmula (I), um estereoisômero, um produto deuterado, um cocristal, um solvato ou um sal farmaceuticamente aceitável do mesmo, em que cada grupo é conforme definido na descrição. O composto tem atividade inibitória da dipeptidil peptidase 1 e pode ser usado para preparar um medicamento para o tratamento de doenças, incluindo doenças obstrutivas das vias aéreas, bronquiectasia, fibrose cística, asma, enfisema e doenças pulmonares obstrutivas crônicas.
BR112023003492A 2020-08-26 2021-08-25 Composto de fórmula (i), composição farmacêutica e uso do composto BR112023003492A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202010871912 2020-08-26
CN202011129809 2020-10-21
CN202110167731 2021-02-07
PCT/CN2021/114500 WO2022042591A1 (zh) 2020-08-26 2021-08-25 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途

Publications (1)

Publication Number Publication Date
BR112023003492A2 true BR112023003492A2 (pt) 2023-05-09

Family

ID=80354645

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023003492A BR112023003492A2 (pt) 2020-08-26 2021-08-25 Composto de fórmula (i), composição farmacêutica e uso do composto

Country Status (13)

Country Link
US (2) US11807635B2 (pt)
EP (1) EP4129989A4 (pt)
JP (1) JP2023539101A (pt)
KR (1) KR20230084134A (pt)
CN (1) CN115996923A (pt)
AU (1) AU2021330865A1 (pt)
BR (1) BR112023003492A2 (pt)
CA (1) CA3190610A1 (pt)
CL (1) CL2023000532A1 (pt)
IL (1) IL300855A (pt)
MX (1) MX2023002371A (pt)
TW (1) TW202214616A (pt)
WO (1) WO2022042591A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020407664A1 (en) 2019-12-20 2022-08-18 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
WO2023160541A1 (zh) * 2022-02-22 2023-08-31 四川海思科制药有限公司 一种含氮杂环化合物的制备方法
WO2023160542A1 (zh) * 2022-02-22 2023-08-31 四川海思科制药有限公司 二肽基肽酶抑制剂化合物的盐及晶型

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462076B2 (en) 2000-06-14 2002-10-08 Hoffmann-La Roche Inc. Beta-amino acid nitrile derivatives as cathepsin K inhibitors
AU2002352126A1 (en) 2001-12-04 2003-06-17 F. Hoffmann-La Roche Ag Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
WO2004110988A1 (en) 2003-06-18 2004-12-23 Prozymex A/S Protease inhibitors
EP2231597A1 (en) 2007-12-12 2010-09-29 AstraZeneca AB Peptidyl nitriles and use thereof as dipeptidyl peptidase i inhibitors
MX2011011661A (es) * 2009-05-07 2011-11-18 Astrazeneca Ab Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
CN102596321B (zh) * 2009-10-29 2014-11-19 詹森药业有限公司 可用作dpp-1抑制剂的炔基衍生物
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
WO2015032942A1 (en) * 2013-09-09 2015-03-12 Prozymex A/S N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
NO2699580T3 (pt) * 2014-01-24 2018-02-24
EP3174879B1 (en) 2014-08-01 2018-07-18 Boehringer Ingelheim International GmbH Substituted oxetanes and their use as inhibitors of cathepsin c
WO2016139355A1 (en) * 2015-03-05 2016-09-09 Prozymex A/S N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
WO2016172496A1 (en) 2015-04-23 2016-10-27 Constellation Pharmaceuticals, Inc. Lsd1 inhibitors and uses thereof
EP3342765B1 (en) 2015-08-29 2021-09-15 Sunshine Lake Pharma Co., Ltd. Cathepsin k inhibitor and application thereof

Also Published As

Publication number Publication date
KR20230084134A (ko) 2023-06-12
AU2021330865A1 (en) 2023-04-27
EP4129989A4 (en) 2024-06-05
US11807635B2 (en) 2023-11-07
CN115996923A (zh) 2023-04-21
US20240059681A1 (en) 2024-02-22
CL2023000532A1 (es) 2023-09-29
IL300855A (en) 2023-04-01
TW202214616A (zh) 2022-04-16
JP2023539101A (ja) 2023-09-13
MX2023002371A (es) 2023-05-19
US20230121807A1 (en) 2023-04-20
EP4129989A1 (en) 2023-02-08
CA3190610A1 (en) 2022-03-03
WO2022042591A1 (zh) 2022-03-03

Similar Documents

Publication Publication Date Title
BR112023003492A2 (pt) Composto de fórmula (i), composição farmacêutica e uso do composto
WO2021207409A3 (en) Small molecule inhibitors of sars-cov-2 viral replication and uses thereof
NO20061254L (no) Farmasoytiske blandinger
JP2015522616A5 (pt)
AR042578A1 (es) Inhibidores de la sintesis de mucina
UA92181C2 (ru) Производные пиримидина и их применение в терапии и в производстве лекарственного средства для предотвращения и/или лечения болезни альцгеймера
NO20063693L (no) Forbindelse og metode for anvendelse
AU2014231648A1 (en) Substituted aromatic compounds and related method for the treatment of fibrosis
RS20080497A (en) Novel low dose pharmaceutical compositions comrising nimesulide, preparation and use thereof
CN107708697B (zh) 纤维化病治疗剂
MX2021014372A (es) Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos.
MX2021014161A (es) Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.
JOP20200314A1 (ar) تركيبات صيدلانية مستقرة لأجهزة إستنشاق جرعات مضغوطة معايرة الجرعة
BRPI0716214A2 (pt) Composições farmacêuticas para o tratamento de infecções fúngicas.
WO2022192665A1 (en) Compositions and methods for inhibiting plpro protease activity and for preventing and treating sars-cov-2 infection
EP3209294B1 (en) Pharmaceutical composition for use in increasing the trophism of nasal mucosa
CN115368425B (zh) 三萜类化合物及其制备方法与抗炎用途
CL2022000079A1 (es) Formulaciones de (s)-3-amino-6-metoxi-n-(3,3,3-trifluoro-2-hidroxi-2-metilpropil)-5-(trifluorometil)picolinamida
EP1670464B1 (en) Topical compositions comprising telmesteine for treating dermatological disorders
BR112021023445A2 (pt) Composição farmacêutica do composto de piridina amina e aplicação da mesma em câncer de pulmão de células não pequenas ros1-positivo
EP3851104A1 (en) Synergic pharmaceutical combination of a selective inhibitor of cyclooxygenase-2 and an anthraquinone derivative
EP2004176B1 (en) USE OF N- ( DIBENZ (b, f) OXEPIN-10-YLMETHYL ) N-METHYL-N- PROP- 2 -YNYLAMINE (OMIGAPIL) FOR THE PROPHYLAXIS AND / OR TREATMENT OF CONGENITAL MUSCULAR DYSTROPHY OR MYOPATHY RESULTING FROM COLLAGEN VI DEFICIENCY
MX2023005801A (es) Derivados de ftalazina como inhibidores de purinoceptor 3 de p2x (p2x3).
BR112022012758A2 (pt) Composto, isômero do mesmo ou sal farmaceuticamente aceitável do mesmo, método de preparação e uso do dito composto, composição farmacêutica e alimento funcional saudável
JP7067031B2 (ja) 固形製剤